Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. by Myklebust, M P et al.
Expression of cyclin D1a and D1b as predictive factors for
treatment response in colorectal cancer
MP Myklebust1, Z Li2, TH Tran2, H Rui2, ES Knudsen2, H Elsaleh3, Ø Fluge4, B Vonen5, HE Myrvold6, S Leh7,
KM Tveit8, RG Pestell2 and O Dahl*,1,4
1Institute of Medicine, Section of Oncology, University of Bergen, Bergen 5021, Norway; 2Department of Cancer Biology, Kimmel Cancer Center, Thomas
Jefferson University, Philadelphia, PA, USA; 3Academic Unit of Internal Medicine, The Australian National University Medical School, The Australian
National University, Canberra ACT 0200, Australia; 4Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen 5021,
Norway; 5Department of Gastrointestinal Surgery, University Hospital of North Norway, Tromsø, Norway; 6Department of Gastrointestinal Surgery,
St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; 7Department of Pathology, Haukeland University Hospital, Bergen 5021, Norway;
8Department of Oncology, Oslo University Hospital and University of Oslo, Oslo, Norway
BACKGROUND: The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their
relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer
(CRC).
METHODS: Protein expression of nuclear cyclin D1a and D1b was assessed by immunohistochemistry in 335 CRC patients treated with
surgery alone or with adjuvant therapy using 5-FU/LEV. The prognostic and predictive value of these two molecular markers and
clinicopathological factors were evaluated statistically in univariate and multivariate survival analyses.
RESULTS: Neither cyclin D1a nor D1b showed any prognostic value in CRC or colon cancer patients. However, high cyclin D1a
predicted benefit from adjuvant therapy measured in 5-year relapse-free survival (RFS) and CRC-specific survival (CSS) compared to
surgery alone in colon cancer (P¼ 0.012 and P¼ 0.038, respectively) and especially in colon cancer stage III patients (P¼ 0.005 and
P¼ 0.019, respectively) in univariate analyses. An interaction between treatment group and cyclin D1a could be shown for RFS
(P¼ 0.004) and CSS (P¼ 0.025) in multivariate analysis.
CONCLUSION: Our study identifies high cyclin D1a protein expression as a positive predictive factor for the benefit of adjuvant 5-FU/
LEV treatment in colon cancer, particularly in stage III colon cancer.
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Colorectal cancer (CRC) is one of the most common malignancies
worldwide, with an incidence of more than 660 000 new cases
annually (Ferlay et al, 2010). The most clinically used prognostic
factor for this cancer type is tumour stage at the time of diagnosis.
At this time, no prognostic or predictive molecular markers are
considered standard in the selection of proper treatment for each
patient. Standard treatment differs, but the present treatment
strategies for colon cancer include surgery, with adjuvant
chemotherapy for patients with locally advanced cancer. Rectal
cancer is mainly treated by surgery, including radiotherapy, with
or without chemotherapy as a sensitiser, prior to surgery to
maximise the treatment effect in advanced stages. Rectal cancer
patients generally do not receive adjuvant chemotherapy in
Norway. Some patients do not respond to the chemotherapy
given, and some could have been cured by surgery alone. Markers
for better prediction of response and benefit from adjuvant
chemotherapy in CRC would clearly improve both patient care and
health-care resource utilisation.
Cyclin D is an important regulator of the cell cycle that drives
progression through G1 in response to mitogenic signals (Sherr,
1995). Type D cyclins form holoenzymes together with cyclin-
dependent kinases (cdks) 4 and 6. Phosphorylation of pRb by
cyclin D facilitates the expression of cyclin E, a positive regulator
of the G1 checkpoint (Lukas et al, 1995; Ohtsubo et al, 1995; Vidal
and Koff, 2000). In mammalian cells, there are three homologous
D-type cyclins: D1, D2 and D3. Among these, cyclin D1 is most
commonly expressed in several human cancers (Diehl, 2002). In
colon cancer, overexpression of nuclear cyclin D1 has been shown
to have a pivotal role in tumorigenesis and cellular metastases
(Arber et al, 1996; McKay et al, 2000a; Mermelshtein et al, 2005).
In colon cancer cell lines, cyclin D1 antisense reduced cellular
growth (Arber et al, 1997) and cyclin D1-deficiency conveyed
resistance to tumour formation induced by APC mutation in
transgenic mice (Hulit et al, 2004). The human cyclin D1 gene is
situated on chromosome 11q13 and has five exons (Inaba et al,
1992; Betticher et al, 1995). A polymorphism, A870G, located at the
splice donor region at the exon–intron 4 boundary produces two
distinct mRNA transcripts named isoforms a and b. The G870
allele results in the cyclin D1a transcript, which is the well-
described form. An alternative splice product, cyclin D1b, arises
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from the A870 allele, which hinders splicing and allows for
read-through into intron 4 and a premature termination of
transcription (Betticher et al, 1995; Holley et al, 2001; Howe and
Lynas, 2001). Thus, isoform b, which is the alternatively spliced
transcript, encodes a truncated protein where the C-terminus of
cyclin D1 is replaced by a shorter sequence from intron 4.
However, individuals homozygous for G/G can still produce cyclin
D1b transcript (Bala and Peltomaki, 2001; Holley et al, 2001). The
half-lives of the two isoforms have been shown to be the same in
model systems, but cyclin D1b was strictly nuclear (Lu et al, 2003;
Solomon et al, 2003). The mentioned studies suggest that cyclin
D1b may be a stronger oncogene, as its capability to transform
cells was increased compared to cyclin D1a. Both isoforms can
stimulate cdk4/6 activity, but cyclin D1b has reduced ability to
phosphorylate pRb (Solomon et al, 2003). Cyclin D1b has been
linked to increased cancer risk in some studies (Kong et al, 2001;
Wang et al, 2002, 2003; Le Marchand et al, 2003;), but the evidence
is not consistent (Cortessis et al, 2003; Schernhammer et al, 2006).
In addition to its cdk-binding function, D-type cyclins have
additional cdk-independent properties in cellular growth, meta-
bolism and cellular differentiation (Fu et al, 2004).
DNA repair proteins have been identified as interaction partners
of cyclin D1 (Li et al, 2010; Jirawatnotai et al, 2011). It has been
shown that cyclin D1a, but not cyclin D1b, recruitment to
chromatin is sufficient for DNA damage response (DDR) to be
initiated (Li et al, 2010). Findings from the same study indicated
that the knockdown of endogenous cyclin D1 in colon cancer cells
reduced the DDR in response to 5-FU treatment. We therefore
hypothesised that treatment response to 5-FU in CRC, especially
the stage III colon cancer patients, could be associated with the
level of cyclin D1 protein, in particular cyclin D1a, in tumour cells
from these patients.
PATIENTS AND METHODS
Study population
Among 425 enrolled patients, a total of 412 patients diagnosed with
operable CRC were found to meet the inclusion criteria in a
prospective and randomised clinical study from January 1993 to
October 1996 (Dahl et al, 2009). The detailed patient characteristics
and inclusion criteria have been presented elsewhere (Dahl et al,
2009). In brief, to be included, histologically diagnosed radical
resection for primary adenocarcinoma in rectum or colon and
regional lymph nodes had to be confirmed. The mean number of
lymph nodes examined was 8.7, a number that reflects the level of
practice at the time in Scandinavia (Derwinger et al, 2007; Edler et al,
2007). Distant metastases were excluded and evaluated by chest
X-ray, ultrasound or computed tomography of the abdomen, in
addition to blood tests including serum CEA. Age limits were set to
18–75 years. In addition, patients were required to not have other
diseases that could interfere with the administration of systemic
chemotherapy or prior cytotoxic therapy. All patients included were
classified as stage II or III according to the TNM classification. The
patients were randomly allocated to treatment with surgery alone
(N¼ 206) or surgery with adjuvant chemotherapy (N¼ 206). None of
the rectal cancer patients had preoperative radiotherapy.
The study was approved by the regional ethics committee,
the Norwegian Medicines Control Authority, and the Data
Inspectorate. All patients gave their written, informed consent
before randomisation.
Chemotherapy and follow-up
Treatment with 5-FU started with a loading course within 42 days
from the date of surgery, giving 450mgm 2 intravenously (i.v.)
daily for 5 days and levamisole 50mg orally  3 for the first 3 days.
Maintenance therapy started 3 weeks later with weekly i.v. 5-FU
450mgm 2, combined with levamisole per os 50mg  3 for 3
days every second week. The maintenance therapy lasted for a total
of 48 weeks. The patients were carefully followed up by the authors
throughout the time period of the study and until 5 years. Standard
follow-up forms were prospectively collected and submitted to the
study centre. Follow-ups were scheduled every 6 months with
clinical examination including chest X-ray, ultrasound of the
abdomen, blood count and s-CEA, and rectoscopy for rectal cancer
patients. Ultrasound was used as the screening method, and
positive findings were confirmed by CT or MR. Colonoscopy was
included every 3 years. Complete follow-up was available for all
patients included. The protocol for detection of relapses was
uniform throughout the patient group over the time of follow-up.
Cancer-specific mortality was defined as death from CRC in
patients with confirmed diagnosis. Autopsy was performed when
the cause of death was uncertain.
Tissue microarray (TMA) and immunohistochemistry (IHC)
Tissue microarray was constructed from formalin-fixed and
paraffin embedded archival tissue samples from 409 of the eligible
412 patients included in the study. Cores of 1.0mm were punched
from representative areas of the primary tumours, from macro-
scopically normal colon or rectal mucosa, and from lymph nodes
with synchronous metastases and mounted in recipient paraffin
blocks using a Manual Tissue Arrayer MTA-1 (Beecher Instruments
Inc., Sun Prairie, WI, USA). For each patient included in the TMA,
the number of samples present in the array varied from one to
three representative samples from each tumour.
Immunohistochemistry and AQUA analyses were performed as
previously described (Mercier et al, 2009). The primary antibodies
used were anti-cytokeratin (AE1/AE3, Dako, Carpinteria, CA, USA)
and anti-cyclin D1a (clone SP4, Lab Vision, Freemont, CA, USA);
the cyclin D1b antibody specificity has been described (Wang et al,
2008). Briefly, after deparaffinisation and rehydration of array
sections, antigen retrieval was performed by microwave treatment
in citrate buffer (pH 6, Dako). Sections were blocked with 10% goat
serum and followed by incubation of primary antibodies to cyclin
D1a or cyclin D1b at a dilution of 1 : 50 for 1 h. Sections were then
washed thrice with TBS and subsequently incubated with mouse
anti-cytokeratin antibody for 1 h. The cyclin D1a and cyclin
D1b antibodies were detected using an anti-rabbit horseradish
peroxidise-conjugated secondary antibody (EnVisionþ , Dako),
followed by incubation with tyramide-Cy5 (Perkin-Elmer, Wal-
tham, MA, USA). Cytokeratin was visualised by further incubating
the sections with an anti-mouse secondary antibody conjugated to
Alexa 488 (Molecular Probes, Eugene, OR, USA). Finally, all
sections were stained with 40,6-diamidino-2-phenylindole (DAPI,
Vector Laboratories, Burlingame, CA, USA) for nuclear visualisa-
tion. Automated quantitative analysis was performed using the
AQUA/PM2000 Imaging Platform (HistoRx, Branford, CT, USA) as
described (Dolled-Filhart et al, 2006). Tissue array slides were
scanned and images of each tissue were captured at different
channels, detecting Alexa 488, Cy5, or DAPI. AQUA software was
then used to identify epithelial masks based on Alexa 488-positive
cytokeratin-expressing cells. DAPI signal was used to identify
nuclei. The cytoplasmic region was determined by subtracting the
nuclear region (DAPI) from the tumour mask (cytokeratin). AQUA
scores for cyclin D1a and cyclin D1b represent average signal
intensities within epithelial cells.
Based on the median staining intensity within each cell compart-
ment, the cyclin D1 isoforms were classified as ‘low’ or ‘high’.
Statistical analysis
The associations between survival and staining of each of the two
isoforms of cyclin D1 were estimated using the Kaplan–Meier
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method, and the log-rank test was used to compare survival
between groups. A Cox regression hazards model was used for the
estimation of the hazard ratio in multivariate analyses, where
tumour stage, treatment group, localisation of tumour, histological
grade, cyclin D1 staining and interaction variables were included.
Relapse-free survival was calculated from the date of randomisa-
tion to the date of clinically confirmed relapse in months or the
last date of follow-up. For the calculation of CSS, death from CRC
was recorded; all other causes of death were handled as censored.
CRC-specific survival was calculated from the date of randomisa-
tion to the date of death caused by CRC or the last date of follow-
up. Representativity of the successfully stained groups for the
whole patient series was checked by t-test and chi-square
goodness-of-fit analyses. All statistical testing was performed
using PASW 18 Statistics (SPSS Inc., Chicago, IL, USA). In two-
sided tests, Po0.05 was considered statistically significant.
RESULTS
Patient characteristics and IHC
Of 412 patients included in this study, 335 patients were
successfully stained and included in the analyses of cyclin D1
isoforms (Figure 1). Of these, 111 experienced relapse and 97 died
of colon cancer. We experienced a significant loss of samples
during staining and scoring. By statistical analyses, the samples
successfully stained for cyclinD1 isoforms were found to be
representative of the whole cohort of 412 patients included in the
initial study (Supplementary Table 4).
For cyclin D1a, the total number of patients with tumours that
were successfully stained and evaluated was 293. Of these, 83 died
from CRC and 96 presented with relapse. The median value for
nuclear cyclin D1a was 23.4, with 146 patients in the ‘low’ group
and 147 in the ‘high’ group. There were 324 patients with
successful cyclin D1b staining of tumour tissue. In this group, the
-cyclin D1a -cyclin D1b
Case 2
Case 1
Figure 1 Immunohistochemistry for cyclin D1a and cyclin D1b using
isoform-specific antibodies. The cyclin D1a antibody used was clone SP4
(Lab Vision), and the cyclin D1b antibody specificity has been described
(Wang et al, 2008). Representative examples of colon cancer samples are
shown. Case 1 expresses nuclear cyclin D1b. Case 2 expresses nuclear
cyclin D1a.
Table 1 Patient characteristics for patients successfully stained for cyclin D1a
Colorectal Colon
Variable
Surgery alone
(N¼ 148)
Adjuvant (5-FU/LEV)
(N¼ 145)
Total
(N¼ 293)
Surgery alone
(N¼102)
Adjuvant (5-FU/LEV)
(N¼108)
Total
(N¼ 210)
Age
Mean (s.d.) 62.8 (8.7) 60.3 (10.0) 61.6 (9.4) 63.4 (8.4) 60.5 (10.2) 62.0 (9.5)
Gender
Male 71 (48%) 76 (52%) 147 (50%) 47 (46%) 53 (49%) 100 (48%)
Female 77 (52%) 69 (48%) 146 (50%) 55 (54%) 55 (51%) 110 (52%)
Stage
Stage II 89 (60%) 84 (58%) 173 (59%) 60 (59%) 68 (63%) 128 (61%)
Stage III 59 (40%) 61 (42%) 120 (41%) 42 (41%) 40 (37%) 82 (39%)
Differentiationa
High/moderate 124 (84%) 119 (82%) 243 (83%) 80 (78%) 89 (82%) 169 (80%)
Low 22 (15%) 24 (17%) 46 (16%) 20 (20%) 18 (17%) 37 (18%)
Histological typeb
Adenocarcinoma 131 (89%) 127 (88%) 258 (88%) 87 (85%) 93 (86%) 180 (86%)
Variantc 12 (8%) 14 (10%) 26 (9%) 10 (10%) 12 (11%) 22 (10%)
Localisation
Proximal 53 (36%) 58 (40%) 111 (38%) 53 (52%) 58 (54%) 111 (53%)
Distal 49 (33%) 50 (34%) 99 (34%) 49 (48%) 50 (46%) 99 (47%)
Rectum 46 (31%) 37 (26%) 83 (28%) 0 0 0
Cyclin D1a
Low 77 (52%) 69 (48%) 146 (50%) 53 (52%) 51 (47%) 104 (50%)
High 71 (48%) 76 (52%) 147 (50%) 49 (48%) 57 (53%) 106 (50%)
Abbreviation: 5-FU/LEV¼ 5-fluorouracil and levamisole. aData regarding differentiation were missing for four patients. bFor histological type, accurate data were missing for nine
patients. cVariant includes mucinous and signet-ring carcinoma.
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number of events was 96 deaths from CRC and 110 relapses. For
cyclin D1b, the median value for the nuclear staining of the
tumours was 45.8, with 162 patients in both the ‘low’ and ‘high’
group. The characteristics for patients included in the analyses of
nuclear cyclin D1a protein expression are shown in Table 1, and in
Supplementary Table 2 for cyclin D1b. Patients in the two
Table 2 Multivariate analyses of characteristics associated with RFS and CSS in colon cancer tumours stage II and III successfully stained for cyclin D1a
RFS CSS
Characteristic HR 95% CI P HR 95% CI P
Stage
Stage III vs II 4.621 2.717–7.862 o0.001 2.789 1.406–5.533 0.003
Tumour localisation
Distal colon vs proximal colon 1.468 0.894–2.408 NS 1.194 0.711–2.004 NS
Hist.grade
Poor vs high/moderate diff. 1.436 0.790–2.612 NS 1.224 0.648–2.312 NS
Treatment group
Adjuvant vs surgery alone 1.454 0.750–2.819 NS 1.327 0.675–2.609 NS
Cyclin D1a status
High vs low 1.649 0.822–3.307 NS 0.322 0.085–1.221 0.096
Interaction
Treatment*cyclin D1a status 0.222 0.080–0.618 0.004 0.290 0.098–0.857 0.025
Interaction
Stage*cyclin D1a statusa — — — 6.634 1.621–27.143 0.008
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; NS¼ not statistically significant. aThe interaction variable stage*cyclinD1a was not significant and thus not included in
the model for RFS.
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Figure 2 Colon cancer stage II and III patients and treatment response according to nuclear cyclin D1a expression. The curves generated by the Kaplan–
Meier method with P-values from the log-rank test show treatment response measured by RFS (A and B) and CSS (C and D) in patients with low nuclear
cyclin D1a (A and C) and high nuclear cyclin D1a (B and D). Blue represents patients treated with surgery plus adjuvant therapy (5-FU/LEV), green
represents those treated with surgery alone. Abbreviations: CSS¼ cancer-specific survival; RFS¼ relapse-free survival.
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treatment groups were well balanced with respect to gender, age,
stage (II and III), tumour site in colon, and cyclin D1a and D1b
status. Associations between cyclin D1a and D1b and other
clinicopathological variables are shown in Supplementary Table 1
and 3, respectively.
Stage is expected to have a prognostic value in colon cancer.
This was indeed true in our colon patients successfully stained for
both cyclin D1a and D1b, with significantly poorer prognosis of
the stage III patients compared to stage II in univariate analyses.
The 5-year RFS for stage II vs stage III was 82% vs 43%,
respectively (Po0.001). For CSS, the results were similar, 90% vs
53%, respectively, for stage II compared to stage III (Po0.001).
Multivariate analyses confirmed stage to be an independent
predictor of survival in this cohort (Table 2).
Prognostic value of cyclin D1a and D1b
To evaluate the prognostic value of nuclear cyclin D1a and D1b,
we analysed survival in the group of patients that had been
randomised to surgery alone. No significant prognostic value for
low or high nuclear cyclin D1a could be demonstrated for either
RFS or CSS for CRC (P¼ 0.333 and P¼ 0.381), colon cancer
(P¼ 0.317 and P¼ 0.688), or colon stage II (P¼ 0.654 and
P¼ 0.512) or III (P¼ 0.104 and P¼ 0.317). Similar results were
obtained for the prognostic value of cyclin D1b for RFS and CSS in
CRC (P¼ 0.419 and P¼ 0.552), colon cancer (P¼ 0.391 and
P¼ 0.508) and colon cancer stage II (P¼ 0.593 and P¼ 0.735)
and III (P¼ 0.531 and P¼ 0.817).
Predictive value of cyclin D1a and D1b
The predictive value of nuclear cyclin D1a and D1b for adjuvant
treatment with 5-FU/LEV was evaluated by comparing RFS and
CSS in patients treated by surgery alone or by adjuvant therapy
with 5-FU/LEV in groups of patients defined by low or high cyclin
D1a or cyclin D1b. A predictive value for nuclear cyclin D1a was
demonstrated for colon cancer, as patients with high expression of
this protein showed longer 5-year RFS and 5-year CSS when
treated with 5-FU/LEV, compared to surgery only (Figure 2). The
Kaplan–Meier analyses showed that 5-year RFS for patients with
low nuclear cyclin D1a treated with surgery only vs adjuvant
therapy (5-FU/LEV) was 69% vs 63% (P¼ 0.307). For CSS, the
5-year rate for both treatment groups in these patients with low
cyclin D1a expression was 77% (P¼ 0.409). In the ‘high’ group, the
5-year RFS was 61% vs 82% for patients treated with surgery alone
or with adjuvant therapy, respectively (P¼ 0.012). There was also a
statistically significant difference in this ‘high’ group for 5-year
CSS (67% vs 84%, P¼ 0.038). No such difference in treatment
response could be demonstrated for the rectal cancer patients or
the total cohort of colorectal patients (results not shown). When
we divided the colon cancer patients into groups defined by stage,
no predictive value of cylinD1a could be demonstrated for stage II
colon cancer patients. Stage III patients with high cyclin D1a
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Figure 3 Colon stage III patients and treatment response according to nuclear cyclin D1a expression. Curves are generated by the Kaplan–Meier method
and P-values are from the log-rank test. Treatment response are measured in RFS (A and B) and CSS (C and D) for low (A and C) vs high (B and D)
expression of nuclear cyclin D1a. Green curves represent patients treated with surgery alone and blue patients treated with surgery plus adjuvant therapy (5-
FU/LEV). Abbreviations: CSS¼ cancer specific survival; RFS¼ relapse-free survival.
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showed a benefit of adjuvant treatment compared to the low cyclin
D1a patients (Figure 3). The 5-year RFS for stage III patients with
high cyclin D1a treated with adjuvant therapy vs surgery alone was
61% and 28%, respectively (P¼ 0.005, Figures 2A and B). A similar
finding was noted for CSS in this ‘high cyclin D1a’ group; the CSS
was 60% in the adjuvant group and 33% in the surgery alone-
treated patients (P¼ 0.019). No significant association between
cyclin D1a and other clinicopathological variables was demon-
strated (Supplementary Table 1). Regarding cyclin D1b, no
predictive value could be demonstrated for CRC or colon cancer
patients (Supplementary Figure 1). However, we observed that the
expected difference in survival between patients of stage III treated
with surgery alone vs adjuvant treatment was lost in patients with
high expression of cyclin D1b (Figure 4).
Multivariate analyses including the colon cancer patients and
the variables nuclear cyclin D1a, treatment group (adjuvant vs
surgery only), tumour localisation (distal vs proximal colon),
tumour histological grade (poor vs high/moderate) and stage (II vs
III) identified stage to be an independent predictor of RFS
(HR¼ 4.62, 95% CI 2.12–7.8, Po0.001) and CSS (HR¼ 2.79, 95%
CI 1.41–5.53, P¼ 0.003) (Table 2). Cyclin D1a status and treatment
did not reach significance. When interaction was tested, it could be
demonstrated for treatment group and nuclear cyclin D1a for both
RFS and CSS (P¼ 0.004 and P¼ 0.025, respectively). No interac-
tion between stage and cyclin D1a was noted for RFS (P¼ 0.092),
but for CSS, this interaction was significant (P¼ 0.008). In stage III
patients, no variables were found significant in multivariate
analyses. No multivariate analyses were performed on stage II
patients or rectal patients, because no variables were found
significant in univariate analyses.
DISCUSSION
In the present study, we investigated the possible roles of the two
cyclin D isoforms, cyclin D1a and D1b, as prognostic or predictive
markers in CRC. Cyclin D1a was identified to be a predictive
marker for benefit from adjuvant treatment with 5-FU/LEV in
colon cancer both when we analysed stages II and III together and
stage III alone. Patients with high expression of nuclear cyclin D1a
in the tumour tissue showed a clear benefit from adjuvant 5-FU/
LEV treatment compared to surgery alone, measured in 5-year RFS
and CSS. Patients with low cyclin D1a had no benefit from
adjuvant treatment. The other isoform, cyclin D1b, was found to be
neither a prognostic nor a predictive marker in CRC or in colon
cancer. On the other hand, the expected benefit from adjuvant
treatment was not found in the ‘high’ cyclin D1b group of colon
cancer stage III. This may indicate that high expression of cyclin
D1b has a negative effect on chemotherapy with 5-FU/LEV.
Cyclin D and cdk4/6 are important regulators of DNA
replication and cell division (Sherr and Roberts, 2004; Besson
et al, 2008). It is widely accepted that cyclin D is a key molecule in
controlling the transition from phase G1 of the cell cycle to S phase
through the mediation of pRb. Consequently, deregulation of
cyclin D1 will promote mitogen-independent proliferation, but
may also affect angiogenesis (Hanai et al, 2002; Yasui et al, 2006),
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Figure 4 Colon cancer stage III patients and Kaplan–Meier estimates of RFS (A and B) and CSS (C and D) after treatment with surgery alone vs surgery
plus adjuvant chemotherapy (5-FU/LEV), according to nuclear cyclin D1b expression. (A and D) Low cyclin D1b. (B and C) High cyclin D1b. Abbreviations:
CSS¼ cancer specific survival; RFS¼ relapse-free survival.
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apoptosis (Albanese et al, 1999), mitochondrial metabolism (Wang
et al, 2006), centrosome duplication (Nelsen et al, 2005) and DDR,
with cyclin D1 interacting with proteins involved in DNA damage
repair, including BRCA1 and Rad51 (Wang et al, 2005; Pontano
et al, 2008; Li et al, 2010; Jirawatnotai et al, 2011). Recent research
has shown that cyclin D1a and b isoforms regulate the DDR
differently (Li et al, 2010). Overexpression of cyclin D1a was shown
to enhance the DDR after double-strand breaks were caused by 5-FU
treatment in cultured colon cancer cells. This study also presents
evidence suggesting that the induction of DDR by cyclin D1a can be
uncoupled from the induction of DNA synthesis. We hypothesised
that the expression of nuclear cyclin D1a in tumour cells could
predict the response to treatment with 5-FU given as adjuvant
therapy in colorectal patients. According to the findings of Li et al,
patients with high expression of cyclin D1a should benefit more
from 5-FU treatment, compared to those with low expression of the
marker. Our results confirm this hypothesis, but we do not exclude
the possibility that the finding of high cyclin D1a as a predictor of
positive response to 5-FU/LEV may be due to higher sensitivity to
chemotherapy caused by the high proliferation rate in the
responsive tumours. Former published work by our group showed
that high expression of the proliferation marker Ki-67 predicted the
effect of 5-FU/LEV in colon cancer (Fluge et al, 2009).
One advantage of the present study is that we were allowed to
analyse surgery alone vs adjuvant therapy as recommended in the
search for prognostic factors (Hayes et al, 1998; Barratt et al, 2002).
The treatment part of our study was planned and conducted at a
time when surgery alone was the main treatment strategy for all
CRC patients in Norway. Adjuvant treatment with 5-FU/LEV was
considered an explorative treatment at that time. Today this would
have been unethical as new and more effective treatment regimens
have been introduced.
Cyclin D1 expression in colon and CRC has been studied by
several research groups, but the reported findings are divergent
(Maeda et al, 1997; McKay et al, 2000b, 2002; Mermelshtein et al,
2005; Kouraklis et al, 2006; Ioachim, 2008; Ogino et al, 2009;
Wangefjord et al, 2011). Some find cyclin D1 to have a prognostic
value on colon or CRC, at least in univariate analysis, but others
find no association between cyclin D1 protein expression and
survival. The findings also diverge in whether low or high cyclin
D1 is favourable. All these studies on cyclin D1 have used IHC, but
the antibody used and the methods for scoring and interpreting
differ. Other factors that differ among the studies are the number
of patients included, and in several studies, no clear statement on
treatment among the included patients is made, for example,
surgery only, different adjuvant treatment regimes. This might, at
least partially, explain the divergent results. To our knowledge, the
present study is the first to investigate whether the cyclin D1
isoforms, D1a and b, have different capabilities to predict
prognosis or response to adjuvant therapy with 5-FU/LEV in
CRC. Unfortunately, our cohort was not large enough to be divided
into a training set and a validation set. The numbers in each
survival group are small and may therefore give rise to somewhat
uncertain analyses. Thus, further investigation is needed to
confirm the clinical usefulness of this molecular marker.
In conclusion, the findings of the present study indicate that
high expression of nuclear cyclin D1a predicts favourable response
for adjuvant therapy with 5-FU. The results also implicate that
high cyclin D1b may be a negative predictor for the effect of
adjuvant treatment with 5-FU/LEV.
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